Table 1

Patient and disease-related characteristics combined with initial management and subsequent lines of therapy

Item	Case 1	Case 2	Case 3
Diagnosis and management (first-line therapy)	• 64 years	• 72 years	• 78 years
	• August 2010	• March 2008	• November 2010
	• PSA =450 ng/mL	• PSA =1,170 ng/mL	• PSA =1,400 ng/mL
	• Skeletal metastasis	• Skeletal metastasis	• Skeletal metastasis
	• Bicalutamide monotherapy	• LHRH analogue therapy	• LHRH analogue + bicalutamide (MAB)
	• Zoledronic acid infusions	• PSA nadir 4.3 in September 2009	• PSA nadir 36.5 in November 2011
	• PSA nadir in November 2010
	• Palliative radiotherapy (spine)
Second-line therapy	• November 2011	• March 2010	• May 2012
	• PSA =23 ng/mL	• PSA =16.3 ng/mL	• PSA =1,400 ng/mL
	• LHRH analogue therapy	• LHRH analogue + bicalutamide (MAB)	• LHRH analogue + DES
Third-line therapy	• September 2012	• September 2010	• October 2013
	• PSA =77 ng/mL	• PSA =46.5 ng/mL	• PSA =868 ng/mL
	• LHRH analogue + bicalutamide (MAB)	• LHRH analogue + DES	• Pelvic nodes + skeletal metastasis
	• Zoledronic acid infusion	• Zoledronic acid infusion	• LHRH analogue + docetaxel
			• Prednisolone
			• Zoledronic acid infusion
Fourth-line therapy	• May 2013	• April 2012
	• PSA =81 ng/mL	• PSA =273 ng/mL
	• No visceral metastasis	• No visceral metastasis
	• LHRH analogue + docetaxel	• LHRH analogue + docetaxel
	• Prednisolone	• Prednisolone
	• Zoledronic acid infusion	• Zoledronic acid infusion
Fifth-line therapy		• June 2013
		• PSA =628 ng/mL
		• No visceral metastasis
		• LHRH analogue + abiraterone
		• Prednisolone
		• Zoledronic acid infusion

PSA, prostate specific antigen; LHRH, luteinizing hormone-releasing hormone; MAB, maximal androgen blockade; DES, diethylstilboestrol.